Cite
Comparative cardiovascular effectiveness of glucagon‐like peptide‐1 receptor agonists versus sodium‐glucose cotransporter‐2 inhibitors in patients with type 2 diabetes: A population‐based cohort study.
MLA
Dong, Yaa‐Hui, et al. “Comparative Cardiovascular Effectiveness of Glucagon‐like Peptide‐1 Receptor Agonists versus Sodium‐glucose Cotransporter‐2 Inhibitors in Patients with Type 2 Diabetes: A Population‐based Cohort Study.” Diabetes, Obesity & Metabolism, vol. 24, no. 8, Aug. 2022, pp. 1623–37. EBSCOhost, https://doi.org/10.1111/dom.14741.
APA
Dong, Y., Chang, C., Lin, J., Yang, W., Wu, L., & Toh, S. (2022). Comparative cardiovascular effectiveness of glucagon‐like peptide‐1 receptor agonists versus sodium‐glucose cotransporter‐2 inhibitors in patients with type 2 diabetes: A population‐based cohort study. Diabetes, Obesity & Metabolism, 24(8), 1623–1637. https://doi.org/10.1111/dom.14741
Chicago
Dong, Yaa‐Hui, Chia‐Hsuin Chang, Jou‐Wei Lin, Wei‐Shun Yang, Li‐Chiu Wu, and Sengwee Toh. 2022. “Comparative Cardiovascular Effectiveness of Glucagon‐like Peptide‐1 Receptor Agonists versus Sodium‐glucose Cotransporter‐2 Inhibitors in Patients with Type 2 Diabetes: A Population‐based Cohort Study.” Diabetes, Obesity & Metabolism 24 (8): 1623–37. doi:10.1111/dom.14741.